EW241115C90000
- 0.05
- 0.000.00%
Edwards Lifesciences Newsroom
Medtech Shouldn't Be Greatly Impacted by RFK Jr. at HHS, Wells Fargo Says
Edwards Lifesciences' (NYSE:EW) Earnings Offer More Than Meets The Eye
We Like The Quality Of Edwards Lifesciences' (NYSE:EW) Earnings
EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Bernstein Liebhard LLP Reminds Edwards Lifesciences Corporation Investors of Upcoming Deadline
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insight
The Past Three Years for Edwards Lifesciences (NYSE:EW) Investors Has Not Been Profitable
Edwards Lifesciences | 10-Q: Q3 2024 Earnings Report
Edwards Lifesciences Insider Sold Shares Worth $1,647,863, According to a Recent SEC Filing
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $81 From $80, Maintains Buy Rating
Edwards Lifesciences Corporation (EW) Fell Due to Missed Earnings Expectations and Weak Guidance
TD Cowen Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Piper Sandler Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
Edwards Life Says Pivotal Study for Evoque Hit One-year Goal
Why Is Boston Scientific Stock Trading Lower On Wednesday?
Shares Of Boston Scientific See Volume; Company To Provide Cardiology Business Update At 4:00 PM EDT
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
Express News | Triscend II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
Daiwa Downgrades Edwards Lifesciences to Neutral From Outperform, Price Target Is $72
JPMorgan Views Edwards Lifesciences TAVR Data Positively